Introduction
The Vaccine sector is entering a new era with the emergence of new, innovative high value products. The market will evolve from being led by inclusion (or otherwise) onto high volume immunization schedules towards a new set of consumer-orientated products.
Scope of this report
- Examination of the prophylactic vaccine market, which targets three main patient groups - pediatric, the elderly and travelers
- Analysis of pipeline activity by indication, company, product type and delivery route
- Review of licensing activity within the vaccine sector, with profiles of key company
- Discussion of strategic options to increase manufacturing capacity
Research and analysis highlights
The launch and continued success of the high-value product, Prevnar, as demonstrated by 2002 year sales of $242m (11% market share - IMS Health), indicates that future vaccine success will rely less heavily on high volume sales of multiple products. The introduction of individual high-value products has the potential to revolutionize the competitive dynamics of the vaccine market away from its traditional high volume immunization schedule reliance.
In order to sustain the recent rate of market growth, companies are expanding vaccine portfolios into novel indications and patient groups. Datamonitor believes that entry into niche disease areas should be treated with caution, as witnessed by the withdrawal of GlaxoSmithKline's LymeRix in early 2002, as a result of poor sales.
Although the current vaccine pipeline is dominated by smaller biotechnology companies, Datamonitor predicts that, in the long-term, there will be a decline in biotech involvement in this sector. This will stem from increased competition and an associated reduction in-licensing deals with major global pharmaceutical companies.
Key reasons to read this report
- Optimize R&D investment through an in-depth understanding of disease epidemiology and the current vaccine pipeline
- Assess key player vaccine activity in terms of product portfolios and partnership networks
- Gain insight into drivers behind current alliance activity and other key industry trends
- Identify alternative manufacturing strategies in order to boost capacity to meet increasing demand
The Vaccine sector is entering a new era with the emergence of new, innovative high value products. 